Ascendis Pharma A/S Company Profile (NASDAQ:ASND)

About Ascendis Pharma A/S

Ascendis Pharma A/S logoAscendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ASND
  • CUSIP:
Key Metrics:
  • Previous Close: $28.24
  • 50 Day Moving Average: $22.07
  • 200 Day Moving Average: $19.93
  • 52-Week Range: $11.92 - $29.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.82
  • P/E Growth: -0.49
  • Market Cap: $699.80M
  • Beta: 0.22
Profitability:
  • Net Margins: -1,158.57%
  • Return on Equity: -65.92%
  • Return on Assets: -58.86%
Debt:
  • Current Ratio: 6.52%
  • Quick Ratio: 6.52%
Additional Links:
Companies Related to Ascendis Pharma A/S:

Analyst Ratings

Consensus Ratings for Ascendis Pharma A/S (NASDAQ:ASND) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.67 (0.01% downside)

Analysts' Ratings History for Ascendis Pharma A/S (NASDAQ:ASND)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017Credit Suisse GroupInitiated CoverageOutperform$28.00View Rating Details
2/8/2017WedbushReiterated RatingOutperform$31.00View Rating Details
12/1/2016Leerink SwannReiterated RatingBuy$24.00View Rating Details
2/23/2015Bank of America CorpInitiated CoverageBuyView Rating Details
2/23/2015Wells Fargo & CompanyInitiated CoverageOutperform$26.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/30/2016        
11/30/2016Q316($0.71)($0.80)ViewN/AView Earnings Details
5/20/2016Q1($0.55)($0.92)ViewN/AView Earnings Details
11/12/2015Q315($0.57)($0.32)ViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.73)ViewN/AView Earnings Details
5/18/2015Q115($0.37)$0.07$2.24 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
Current Year EPS Consensus Estimate: $-2.36 EPS
Next Year EPS Consensus Estimate: $-2.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.77)($0.77)($0.77)
Q3 20162($0.87)($0.69)($0.78)
Q4 20162($0.64)($0.58)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ascendis Pharma A/S (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ascendis Pharma A/S (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Ascendis Pharma A/S (NASDAQ:ASND)
DateHeadline
finance.yahoo.com logoAscendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients (NASDAQ:ASND)
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients (NASDAQ:ASND)
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logo4:07 pm Ascendis Pharma announces the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocrinology and Metabolism (NASDAQ:ASND)
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logo4:07 pm Ascendis Pharma announces the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocrinology and Metabolism (NASDAQ:ASND)
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logoAscendis (ASND) Catches Eye: Stock Gains 7.2% in Session (NASDAQ:ASND)
finance.yahoo.com - February 16 at 8:34 AM
us.rd.yahoo.com logoCoverage initiated on Ascendis Pharma by Credit Suisse (NASDAQ:ASND)
us.rd.yahoo.com - February 9 at 8:49 PM
marketexclusive.com logoAnalyst Activity – Credit Suisse Group Initiates Coverage On Ascendis Pharma A/S (NASDAQ:ASND) With a Outperform (NASDAQ:ASND)
marketexclusive.com - February 9 at 3:49 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Presentation at the LEERINK Partners 6th Annual Global Healthcare Conference on February 15th (NASDAQ:ASND)
finance.yahoo.com - February 7 at 4:35 PM
News IconRestless Legs Syndrome Market Report Overview, Development and Comparative Analysis 2016 (NASDAQ:ASND)
empowerednews.net - January 3 at 9:20 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Presentation at 35th Annual J.P. Morgan Healthcare Conference on January 9 (NASDAQ:ASND)
finance.yahoo.com - January 3 at 9:20 PM
4-traders.com logoIntercept Pharmaceuticals Inc : Blog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition (NASDAQ:ASND)
www.4-traders.com - December 15 at 3:28 PM
finance.yahoo.com logoBlog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition (NASDAQ:ASND)
finance.yahoo.com - December 15 at 3:28 PM
finance.yahoo.com logoWhy Ascendis Pharma (ASND) Stock Might be a Great Pick (NASDAQ:ASND)
finance.yahoo.com - December 14 at 4:22 PM
News IconAre Hedge Funds On To Something With Ascendis Pharma A/S (ASND) Bullishness? (NASDAQ:ASND)
feedproxy.google.com - December 8 at 5:28 PM
capitalcube.com logoAscendis Pharma A/S :ASND-US: Earnings Analysis: Q3, 2016 By the Numbers : December 2, 2016 (NASDAQ:ASND)
www.capitalcube.com - December 2 at 10:29 AM
4-traders.com logoAscendis Pharma A/S : reports 3Q loss (NASDAQ:ASND)
www.4-traders.com - December 1 at 8:44 PM
us.rd.yahoo.com logoEdited Transcript of ASND earnings conference call or presentation 30-Nov-16 9:30pm GMT (NASDAQ:ASND)
us.rd.yahoo.com - December 1 at 3:41 PM
us.rd.yahoo.com logoAscendis Pharma A/S Reports Third Quarter 2016 Financial Results (NASDAQ:ASND)
us.rd.yahoo.com - November 30 at 8:39 PM
sg.finance.yahoo.com logoAscendis Pharma reports 3Q loss (NASDAQ:ASND)
sg.finance.yahoo.com - November 30 at 8:39 PM
biz.yahoo.com logoQ3 2016 Ascendis Pharma A/S Earnings Release - After Market Close (NASDAQ:ASND)
biz.yahoo.com - November 30 at 9:33 AM
News IconAscendis Pharma A/S to Report Third Quarter 2016 Financial Results and (NASDAQ:ASND)
www.biomedreports.com - November 16 at 9:29 PM
finance.yahoo.com logoAscendis Pharma A/S to Report Third Quarter 2016 Financial Results and Host Conference Call on November 30 (NASDAQ:ASND)
finance.yahoo.com - November 16 at 9:29 PM
publicnow.com logoAscendis Pharma A/S Announces Participation in Two Upcoming Investor Conferences (NASDAQ:ASND)
www.publicnow.com - November 2 at 10:11 PM
streetinsider.com logoAscendis Pharma (ASND) Commences $100M Public Offering of ADSs (NASDAQ:ASND)
www.streetinsider.com - October 20 at 9:31 PM
4-traders.com logoAscendis Pharma A/S : Announces Proposed Public Offering of ADSs (NASDAQ:ASND)
www.4-traders.com - October 20 at 9:31 AM
seekingalpha.com logoAscendis Pharma prices equity offering (NASDAQ:ASND)
seekingalpha.com - October 20 at 9:31 AM
publicnow.com logoAscendis Pharma A/S Announces Pricing of Public Offering of ADSs (NASDAQ:ASND)
www.publicnow.com - October 19 at 8:28 AM
nasdaq.com logoEuropean ADRs Edge Lower as Telecommunication Stocks See Mixed Fortunes (NASDAQ:ASND)
www.nasdaq.com - September 27 at 3:36 PM
nasdaq.com logoEuropean ADRs Edge Lower as Banks Retreat (NASDAQ:ASND)
www.nasdaq.com - September 26 at 3:43 PM
streetinsider.com logoWedbush Starts Ascendis Pharma (ASND) at Outperform (NASDAQ:ASND)
www.streetinsider.com - September 26 at 3:43 PM
finance.yahoo.com logoCoverage initiated on Ascendis Pharma by Wedbush (NASDAQ:ASND)
finance.yahoo.com - September 26 at 3:43 PM
finance.yahoo.com logoAscendis Pharma A/S (ASND): Moving Average Crossover Alert (NASDAQ:ASND)
finance.yahoo.com - September 26 at 3:43 PM
publicnow.com logoAscendis Pharma A/S Announces Webcast of R&D Update (NASDAQ:ASND)
www.publicnow.com - September 23 at 8:30 AM
finance.yahoo.com logoAscendis Pharma A/S Announces Participation in 2016 Morgan Stanley Global Healthcare Conference on September 14 (NASDAQ:ASND)
finance.yahoo.com - September 13 at 8:27 AM
finance.yahoo.com logoAscendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting (NASDAQ:ASND)
finance.yahoo.com - September 9 at 8:25 AM
reuters.com logoBRIEF-Ascendis Pharma reports Q2 loss per share EUR 0.53 (NASDAQ:ASND)
www.reuters.com - September 1 at 12:03 PM
publicnow.com logoAscendis Pharma A/S Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ASND)
www.publicnow.com - September 1 at 12:03 PM
biz.yahoo.com logoQ2 2016 Ascendis Pharma A/S Earnings Release - After Market Close (NASDAQ:ASND)
biz.yahoo.com - August 31 at 8:24 AM
finance.yahoo.com logoCan the Rally in Ascendis Pharma (ASND) Shares Continue? (NASDAQ:ASND)
finance.yahoo.com - August 26 at 11:43 AM
live-pr.com logoNew Report Available: Ascendis Pharma A/S (ASND) - Financial and Strategic SWOT Analysis Review (NASDAQ:ASND)
www.live-pr.com - August 22 at 8:44 PM
publicnow.com logoAscendis Pharma A/S to Report Second Quarter 2016 Financial Results and Host Conference Call on August 31 (NASDAQ:ASND)
www.publicnow.com - August 19 at 11:59 AM
businesswire.com logoSymphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director (NASDAQ:ASND)
www.businesswire.com - August 18 at 12:00 PM
finance.yahoo.com logoAscendis Pharma A/S Announces R&D Update to Review Expanded Pipeline and Long-term Strategic Outlook (NASDAQ:ASND)
finance.yahoo.com - August 15 at 9:08 PM
News IconAscendis Pharma begins phase 3 study of transcon growth hormone in children with GHD (NASDAQ:ASND)
www.pharmabiz.com - August 13 at 11:48 AM
seekingalpha.com logoAscendis Pharma commences late-stage study supporting lead product candidate (NASDAQ:ASND)
seekingalpha.com - August 12 at 12:11 PM
News IconAscendis Pharma starts phase 3 pediatric GHD study (NASDAQ:ASND)
www.bioportfolio.com - August 12 at 12:11 PM
prnewswire.com logoAscendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth ... (NASDAQ:ASND)
www.prnewswire.com - August 12 at 12:11 PM
streetinsider.com logoAscendis Pharma (ASND) Initiates Phase 3 Trial for TransCon Growth Hormone in Children with GHD (NASDAQ:ASND)
www.streetinsider.com - August 12 at 12:11 PM
publicnow.com logoAscendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency (NASDAQ:ASND)
www.publicnow.com - August 11 at 12:51 PM
News IconAscendis Pharma appoints Scott T. Smith as CFO (NASDAQ:ASND)
www.poandpo.com - August 9 at 10:12 PM

Social

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Where is Ascendis Pharma A/S's stock going? Where will Ascendis Pharma A/S's stock price be in 2017?

3 equities research analysts have issued 12-month target prices for Ascendis Pharma A/S's stock. Their predictions range from $24.00 to $31.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $27.67 in the next twelve months.

When will Ascendis Pharma A/S announce their earnings?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 30th 2016.

What are analysts saying about Ascendis Pharma A/S stock?

Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:

  • According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (2/16/2017)

  • Leerink Swann analysts commented, "We project that ASND’s cash position at YE16 will be ~ $180M and expect this will fund operations through completion of its TransCon Growth Hormone study in 2018." (12/1/2016)

Who owns Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include RA Capital Management, LLC (17.10%), FMR LLC (12.51%), Orbimed Advisors LLC (10.78%), Vivo Capital LLC (7.01%), Deerfield Management Co. (4.17%) and EcoR1 Capital LLC (3.87%).

Who sold Ascendis Pharma A/S stock? Who is selling Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.

Who bought Ascendis Pharma A/S stock? Who is buying Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., EcoR1 Capital LLC, FMR LLC, Orbimed Advisors LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Foresite Capital Management III LLC and Marshall Wace LLP.

How do I buy Ascendis Pharma A/S stock?

Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ascendis Pharma A/S stock cost?

One share of Ascendis Pharma A/S stock can currently be purchased for approximately $27.67.

Ascendis Pharma A/S (NASDAQ:ASND) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Earnings History Chart

Earnings by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Dividend History Chart

Dividend Payments by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Last Updated on 2/22/2017 by MarketBeat.com Staff